Cargando…

New Surgical Circulatory Support System Outcomes

We report the first U.S. experience of the recently approved micro-axial surgical heart pump for the treatment of ongoing cardiogenic shock following acute myocardial infarction (AMICGS), postcardiotomy cardiogenic shock (PCCS), cardiomyopathy including myocarditis, high-risk percutaneous coronary i...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramzy, Danny, Soltesz, Edward, Anderson, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316144/
https://www.ncbi.nlm.nih.gov/pubmed/32541335
http://dx.doi.org/10.1097/MAT.0000000000001194
_version_ 1783550383278260224
author Ramzy, Danny
Soltesz, Edward
Anderson, Mark
author_facet Ramzy, Danny
Soltesz, Edward
Anderson, Mark
author_sort Ramzy, Danny
collection PubMed
description We report the first U.S. experience of the recently approved micro-axial surgical heart pump for the treatment of ongoing cardiogenic shock following acute myocardial infarction (AMICGS), postcardiotomy cardiogenic shock (PCCS), cardiomyopathy including myocarditis, high-risk percutaneous coronary intervention (HRPCI), and coronary artery bypass surgery (HRCABG). Demographic, procedural, hemodynamic, and outcome data were obtained from the manufacturer’s quality database of all Impella 5.5 implants at three centers. Fifty-five patients underwent an Impella 5.5 implant for cardiomyopathy (45%), AMICGS (29%), PCCS (13%), preop CABG (5%), OPCAB (4%), and other (4%). Thirty-five patients (63.6%) were successfully weaned off device with recovery of native heart function. Eleven patients (20.0%) were bridged to another therapy, two patients (3.6%) expired while on support, and in seven patients (12.7%) care was withdrawn. Overall survival was 83.6%. There were no device-related strokes, hemolysis, or limb ischemia observed. Four patients experienced purge sidearm damage, resulting in a pump stop in two patients. The new micro-axial surgical heart pump demonstrated successful clinical and device performance in providing both full hemodynamic support and ventricular unloading for patients with AMICGS, decompensated cardiomyopathy, and high-risk cardiac procedures. In this early U.S. experience, 83.6% of patients survived to explant with 76.1% of these patients recovering native heart function.
format Online
Article
Text
id pubmed-7316144
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-73161442020-07-09 New Surgical Circulatory Support System Outcomes Ramzy, Danny Soltesz, Edward Anderson, Mark ASAIO J Adult Circulatory Support We report the first U.S. experience of the recently approved micro-axial surgical heart pump for the treatment of ongoing cardiogenic shock following acute myocardial infarction (AMICGS), postcardiotomy cardiogenic shock (PCCS), cardiomyopathy including myocarditis, high-risk percutaneous coronary intervention (HRPCI), and coronary artery bypass surgery (HRCABG). Demographic, procedural, hemodynamic, and outcome data were obtained from the manufacturer’s quality database of all Impella 5.5 implants at three centers. Fifty-five patients underwent an Impella 5.5 implant for cardiomyopathy (45%), AMICGS (29%), PCCS (13%), preop CABG (5%), OPCAB (4%), and other (4%). Thirty-five patients (63.6%) were successfully weaned off device with recovery of native heart function. Eleven patients (20.0%) were bridged to another therapy, two patients (3.6%) expired while on support, and in seven patients (12.7%) care was withdrawn. Overall survival was 83.6%. There were no device-related strokes, hemolysis, or limb ischemia observed. Four patients experienced purge sidearm damage, resulting in a pump stop in two patients. The new micro-axial surgical heart pump demonstrated successful clinical and device performance in providing both full hemodynamic support and ventricular unloading for patients with AMICGS, decompensated cardiomyopathy, and high-risk cardiac procedures. In this early U.S. experience, 83.6% of patients survived to explant with 76.1% of these patients recovering native heart function. Lippincott Williams & Wilkins 2020-06-10 2020-07 /pmc/articles/PMC7316144/ /pubmed/32541335 http://dx.doi.org/10.1097/MAT.0000000000001194 Text en Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the ASAIO. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Adult Circulatory Support
Ramzy, Danny
Soltesz, Edward
Anderson, Mark
New Surgical Circulatory Support System Outcomes
title New Surgical Circulatory Support System Outcomes
title_full New Surgical Circulatory Support System Outcomes
title_fullStr New Surgical Circulatory Support System Outcomes
title_full_unstemmed New Surgical Circulatory Support System Outcomes
title_short New Surgical Circulatory Support System Outcomes
title_sort new surgical circulatory support system outcomes
topic Adult Circulatory Support
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316144/
https://www.ncbi.nlm.nih.gov/pubmed/32541335
http://dx.doi.org/10.1097/MAT.0000000000001194
work_keys_str_mv AT ramzydanny newsurgicalcirculatorysupportsystemoutcomes
AT solteszedward newsurgicalcirculatorysupportsystemoutcomes
AT andersonmark newsurgicalcirculatorysupportsystemoutcomes